Findings

What do systematic reviews say?

27 questions · 27 findings · 14 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 3 · 11.1%GRADE not reported 1 · 3.7%Very low 2 · 7.4%Low 7 · 25.9%Moderate 12 · 44.4%High 2 · 7.4%

Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone

Overall survival (OS) · platinum‐sensitive recurrent EOC

Chemotherapy with TKI followed by TKI maintenance showed no clear difference in overall survival (OS) compared with chemotherapy alone (low certainty).

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
HR 0.86 [0.67, 1.11]
1 study · 282 participants
Low

Bevacizumab plus chemotherapy vs chemotherapy alone

Overall survival (OS) · recurrent platinum‐resistant EOC

Chemotherapy with bevacizumab leads to lower overall survival (OS) compared with chemotherapy alone (high certainty).

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
HR 0.73 [0.61, 0.86]
5 studies · 778 participants
High

Chemotherapy with TKI vs chemotherapy alone

Overall survival (OS) · recurrent platinum‐resistant EOC

Chemotherapy with TKI showed no clear difference in overall survival (OS) compared with chemotherapy alone (moderate certainty).

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
HR 0.85 [0.68, 1.08]
8 studies · 940 participants
Moderate

Single‐immune checkpoint inhibitors (ICIs) vs chemotherapy alone

Overall survival (OS) · People with advanced non‐small cell lung cancer

Single‐immune checkpoint inhibitors (ICIs) probably leads to lower overall survival (OS) compared with chemotherapy (moderate certainty).

1 finding from 1 review

Single or combined immune checkpoint inhibitors compared to first‐line platinum‐based chemotherapy with or without… 2021 · Cochrane Headline outcomes only
HR 0.68 [0.6, 0.76]
6 studies · 2111 participants
Moderate

Combined immune checkpoint inhibitors (ICIs) vs chemotherapy alone

Overall survival (OS) · People with advanced non‐small cell lung cancer

Combined immune checkpoint inhibitors (ICIs) probably leads to lower overall Survival (OS) compared with chemotherapy (moderate certainty).

1 finding from 1 review

Single or combined immune checkpoint inhibitors compared to first‐line platinum‐based chemotherapy with or without… 2021 · Cochrane Headline outcomes only
HR 0.72 [0.59, 0.89]
2 studies · 612 participants
Moderate

Intervention not reported

Overall survival ‐ trials of mTNBC participants · women with metastatic triple‐negative breast cancer (mTNBC)

The intervention showed no clear difference in overall survival ‐ trials of mTNBC participants (low certainty).

1 finding from 1 review

Platinum‐containing regimens for metastatic breast cancer 2017 · Cochrane Headline outcomes only
HR 0.75 [0.57, 1]
3 studies · 391 participants
Low

Intervention not reported

Overall survival ‐ trials of metastatic breast cancer participants unselected for TNBC · women with metastatic breast cancer unselected for triple‐negative breast cancer (TNBC)

The intervention showed no clear difference in overall survival ‐ trials of metastatic breast cancer participants… (high certainty).

1 finding from 1 review

Platinum‐containing regimens for metastatic breast cancer 2017 · Cochrane Headline outcomes only
HR 1.01 [0.92, 1.12]
16 studies · 2531 participants
High